Stay updated with breaking news from Jay Flatley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Carl Icahn wants former Illumina CEO Jay Flatley back at the San Diego genetic sequencing firm, the Wall Street Journal reported on Wednesday, as the activist investor intensifies his proxy fight.
Low insider confidence is not a good look for RIVN stock, as it may indicate slim chances the struggling EV maker makes a recovery.
Activist investor Carl C. Icahn says he will nominate three allies to Illumina's board who will press the company to sell off cancer blood test developer Grail.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
/PRNewswire/ -- Time BioVentures, an early-stage life sciences venture firm, today announced the close of its first fund, Time BioVentures I, LP with $100...